



## Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

February 8, 2023

CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:

**SVB Securities Global Biopharma Conference**

4:20 pm ET on Tuesday, February 14, 2023.

**Cowen Annual Healthcare Conference**

2:50 pm ET on Monday, March 6, 2023.

**Oppenheimer Annual Healthcare Conference**

10:40 am ET on Monday, March 13, 2023.

The presentations will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal [website](#) after the events.

**About Madrigal Pharmaceuticals**

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's lead candidate, resmetrom, is a once daily, oral, thyroid hormone receptor (THR)- $\beta$  selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

**Investor Contact**

Alex Howarth, Madrigal Pharmaceuticals, Inc., [IR@madrigalpharma.com](mailto:IR@madrigalpharma.com)

**Media Contact**

Christopher Frates, Madrigal Pharmaceuticals, Inc., [media@madrigalpharma.com](mailto:media@madrigalpharma.com)



Source: Madrigal Pharmaceuticals, Inc.